Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 90-96

  Wang, Jian an ^a,b   Chen, Wen ai ^a,b   Wang, Yifan ^a,b   Zhang, Songzhao ^a   Bi, Honghao ^a,b   Hong, Bo ^b   Luo, Yueqiu ^b   Daugherty, Alan ^c   Xie, Xiaojie ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Abdominal aortic aneurysm; Angiotensin II; Atherosclerosis; Atorvastatin; Rosuvastatin

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; DRINKING WATER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSUVASTATIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; AORTA ROOT; ARTERY DIAMETER; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; INTIMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHAM PROCEDURE;

ANGIOTENSIN II; ANIMAL FEED; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; FLUOROBENZENES; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 79960235544     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.005     Document Type: Article

References (30)

1. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105:1605-1612.
2. Daugherty A., Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci 1999, 892:108-118.
3. Cassis L.A., Gupte M., Thayer S., et al. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 2009, 296:H1660-H1665.
4. Liao S., Miralles M., Kelley B.J., et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001, 33:1057-1064.
5. Frolkis J.P., Pearce G.L., Sprecher D.L. Implications of 2001 cholesterol treatment guidelines based on a retrospective analysis of a high-risk patient cohort. Am J Cardiol 2002, 89:765-766.
6. Orem C., Orem A., Calapoglu M., et al. Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy. Acta Cardiol 2002, 57:421-425.
7. Strandberg T.E., Feely J., Sigurdsson E.L. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10mg/d and atorvastatin 10mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004, 26:1821-1833.
8. Ortego M., Bustos C., Hernandez-Presa M.A., et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147:253-261.
9. Kolyada A.Y., Fedtsov A. Madias NE. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 2001, 38:1024-1029.
10. Grothusen C., Bley S., Selle T., et al. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005, 182:57-69.
11. Monetti M., Canavesi M., Camera M., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 2007, 55:441-449.
12. Kajimoto K., Miyauchi K., Kasai T., et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009, 206:505-511.
13. Wilson W.R., Evans J., Bell P.R., et al. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005, 30:259-262.
14. Van K.J.P., Flu W.J., Witteveen O.P., et al. The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms. J Cardiovasc Surg (Torino) 2009, 50:599-609.
15. Shiraya S., Miyake T., Aoki M., et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009, 202:34-40.
16. Barisione C., Charnigo R., Howatt D.A., et al. Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J Vasc Surg 2006, 44:372-376.
17. Daugherty A., Manning M.W., Cassis L.A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001, 134:865-870.
18. Daugherty A., Whitman S.C. Quantification of atherosclerosis in mice. Methods Mol Biol 2003, 209:293-309.
19. Lu H., Rateri D.L., Daugherty A. Immunostaining of mouse atherosclerotic lesions. Methods Mol Med 2007, 139:77-94.
20. Xu D.H., Ruan Z.R., Zhou Q., et al. Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2006, 20:2369-2375.
21. McTaggart F., Buckett L., Davidson R., et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001, 87:28B-32B.
22. Shum Y.Y., Huang N., Walter G., et al. Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices. Ther Drug Monit 1998, 20:41-49.
23. Zhang Y., Naggar J.C., Welzig C.M., et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 2009, 29:1764-1771.
24. Tham D.M., Martin-McNulty B., Wang Y.X., et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002, 11:21-30.
25. Keidar S., Attias J., Heinrich R., et al. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 1999, 146:249-257.
26. Chen J., Li D., Schaefer R.F., et al. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol 2004, 44:446-452.
27. Ni W., Kitamoto S., Ishibashi M., et al. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 2004, 24:534-539.
28. Daugherty A., Rateri D.L., Charo I.F., et al. Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) 2010, 118:681-689.
29. Schmeisser A., Marquetant R., Illmer T., et al. The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis 2005, 178:83-94.
30. Karlsson L., Bergqvist D., Lindback J., et al. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg 2009, 37:420-424.